LGND Ligand Pharmaceuticals
- 84.928
- +0.858+1.02%
Ligand Pharmaceuticals News
Form 144 | Ligand Pharmaceuticals(LGND.US) Officer Proposes to Sell 434.5K in Common Stocks
SEC FILLINGS DISCLOSED/ May 13, $Ligand Pharmaceuticals(LGND.US)$、$LIGAND PHARMACEUTICAL INC(LGNDZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNXZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNYZ.US)$、$LIGAND PHARMACEUTIC
Ligand Pharmaceuticals(LGND.US) Officer Sells US$830.45K in Common Stock
$Ligand Pharmaceuticals(LGND.US)$ Officer Reardon Andrew sold 10,000 shares of common stock on May 9, 2024 at an average price of $83.0449 for a total value of $830.45K.Source: Announcement What is st
Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing
Andrew Reardon, Chief Legal Officer, on May 09, 2024, sold 10,000 shares in Ligand Pharmaceuticals (LGND) for $830,449. Following the Form 4 filing with the SEC, Reardon has control over a total of 22
Form 144 | Ligand Pharmaceuticals(LGND.US) Officer Proposes to Sell 830.45K in Common Stocks
SEC FILLINGS DISCLOSED/ May 9, $Ligand Pharmaceuticals(LGND.US)$、$LIGAND PHARMACEUTICAL INC(LGNDZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNXZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNYZ.US)$、$LIGAND PHARMACEUTICA
10% Of This Ligand Pharmaceuticals Insider's Holdings Were Sold
From what we can see, insiders were net sellers in Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND ) during the past 12 months. That is, insiders sold the stock in greater numbers than they purchas
10-Q: Quarterly report
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks were slipping late Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each easing around 0.3%. The iShares Biotechnology ETF (IBB
Ligand Pharmaceuticals Shares Rise After Q1 Adjusted Earnings, Revenue Beat Views
Ligand Pharmaceuticals (LGND) shares were up nearly 11% in recent trading Wednesday, a day after the company's Q1 adjusted net income and revenue exceeded consensus. The company reported Q1 adjusted e
Earnings Call Summary | Ligand Pharmaceuticals(LGND.US) Q1 2024 Earnings Conference
The following is a summary of the Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Call Transcript:Financial Performance:Ligand Pharmaceuticals reported a Q1 2024 revenue of $31 million com
Ligand Pharmaceuticals Price Target Maintained With a $144.00/Share by HC Wainwright & Co.
Ligand Pharmaceuticals Price Target Maintained With a $144.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $144 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $144 price target.
Ligand Pharmaceuticals Inc (LGND) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...
Ligand Pharmaceuticals Inc (LGND) Reports Mixed Q1 2024 Results: Misses Revenue Estimates but ...
Ligand Pharmaceuticals Reaffirms FY24 Adj. EPS $4.25-$4.75 Vs $4.44 Est.; Revenue $130M-$142M Vs $137.680M Est.
Ligand Pharmaceuticals Reaffirms FY24 Adj. EPS $4.25-$4.75 Vs $4.44 Est.; Revenue $130M-$142M Vs $137.680M Est.
Ligand Pharmaceuticals Reaffirming Its 2024 Fincl Guidance >LGND
Ligand Pharmaceuticals Reaffirming Its 2024 Fincl Guidance >LGND
Ligand Pharmaceuticals Inc Q1 Profit Increases, Beats Estimates
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q1 Revenue $31M, Vs. Street Est of $27.9M
04:03 PM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q1 Revenue $31M, vs. Street Est of $27.9M
Press Release: Ligand Reports First Quarter 2024 Financial Results
Ligand Reports First Quarter 2024 Financial Results Conference Call Begins at 4:30 p.m. Eastern Time Today JUPITER, Fla.--(BUSINESS WIRE)--May 07, 2024-- Ligand Pharmaceuticals Incorporated (Nasdaq
Ligand Pharmaceuticals 1Q Net $86.1M >LGND
Ligand Pharmaceuticals 1Q Net $86.1M >LGND
Ligand Reports First Quarter 2024 Financial Results
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions.
Analysis
Price Target
No Data
